GlycoMimetics, Inc. (GLYC) Reaches $25.82 52-Week High; Lincoln Educational Services (LINC) Sentiment Is 0.73

February 15, 2018 - By Darrin Black

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) hit a new 52-week high and has $27.37 target or 6.00% above today’s $25.82 share price. The 5 months bullish chart indicates low risk for the $886.60M company. The 1-year high was reported on Feb, 15 by Barchart.com. If the $27.37 price target is reached, the company will be worth $53.20 million more. The stock increased 4.79% or $1.18 during the last trading session, reaching $25.82. About 308,471 shares traded. GlycoMimetics, Inc. (NASDAQ:GLYC) has risen 81.25% since February 15, 2017 and is uptrending. It has outperformed by 64.55% the S&P500.

Lincoln Educational Services Corporation, together with its subsidiaries, provides various career-oriented post-secondary education services in the United States. The company has market cap of $42.02 million. It offers bachelor's degree, associate's degree, and diploma and certificate programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology areas to recent high school graduates and working adults. It currently has negative earnings. The firm operates 28 schools in 15 states under the Lincoln Technical Institute, Lincoln College of Technology, Lincoln College of New England, Lincoln Culinary Institute, Euphoria Institute of Beauty Arts and Sciences, and associated brand names.

Investors sentiment decreased to 1.08 in 2017 Q3. Its down 0.83, from 1.91 in 2017Q2. It turned negative, as 13 investors sold GlycoMimetics, Inc. shares while 11 reduced holdings. 5 funds opened positions while 21 raised stakes. 28.80 million shares or 2.36% less from 29.49 million shares in 2017Q2 were reported. Vanguard reported 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Orbimed Advsr Ltd Com has 0.05% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 337,588 shares. First Personal Fincl Svcs holds 0.01% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC) for 1,892 shares. Endurant Capital Limited Partnership stated it has 17,607 shares or 0.07% of all its holdings. Moreover, Morgan Stanley has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC) for 95 shares. State Street Corporation invested in 0% or 25,600 shares. Bnp Paribas Arbitrage owns 72 shares for 0% of their portfolio. Baker Bros Advisors Lp reported 0.06% in GlycoMimetics, Inc. (NASDAQ:GLYC). Thompson Davis & reported 750 shares or 0.02% of all its holdings. Price T Rowe Associate Incorporated Md owns 1.10 million shares for 0% of their portfolio. Citadel Advsrs Ltd Llc owns 58,422 shares or 0% of their US portfolio. 77,056 were reported by Parametric Port Associate Limited. Td Asset Mgmt holds 25,300 shares or 0% of its portfolio. Jennison Limited Liability Co accumulated 0.02% or 1.59M shares. Susquehanna International Ltd Liability Partnership accumulated 116,629 shares.

Analysts await GlycoMimetics, Inc. (NASDAQ:GLYC) to report earnings on March, 7. They expect $-0.26 earnings per share, up 27.78% or $0.10 from last year’s $-0.36 per share. After $-0.24 actual earnings per share reported by GlycoMimetics, Inc. for the previous quarter, Wall Street now forecasts 8.33% negative EPS growth.

Among 5 analysts covering GlycoMimetics (NASDAQ:GLYC), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GlycoMimetics has $35.0 highest and $8.50 lowest target. $20.50’s average target is -20.60% below currents $25.82 stock price. GlycoMimetics had 16 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, August 10 by Zacks. The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) has “Buy” rating given on Tuesday, June 6 by Stifel Nicolaus. The rating was maintained by Jefferies on Friday, July 7 with “Buy”. Jefferies maintained the shares of GLYC in report on Tuesday, September 12 with “Buy” rating. On Tuesday, December 12 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Thursday, February 8 by Roth Capital. The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) earned “Buy” rating by Stifel Nicolaus on Thursday, August 3. The firm has “Buy” rating by Roth Capital given on Wednesday, November 1. The firm has “Buy” rating given on Monday, October 23 by Roth Capital. The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) earned “Buy” rating by Jefferies on Monday, June 5.

Since September 18, 2017, it had 0 buys, and 2 selling transactions for $56,020 activity. $26,000 worth of GlycoMimetics, Inc. (NASDAQ:GLYC) was sold by Thackray Helen M. on Monday, September 18.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $886.60 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

It closed at $1.7 lastly. It is down 108.84% since February 15, 2017 and is uptrending. It has outperformed by 92.14% the S&P500.

Analysts await Lincoln Educational Services Corporation (NASDAQ:LINC) to report earnings on March, 7. They expect $0.32 EPS, up 113.33% or $0.17 from last year’s $0.15 per share. LINC’s profit will be $7.91 million for 1.33 P/E if the $0.32 EPS becomes a reality. After $-0.06 actual EPS reported by Lincoln Educational Services Corporation for the previous quarter, Wall Street now forecasts -633.33% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts